Drugs / REGEND003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07275788 | Jan 2026 → Dec 2027 expected | type 2 diabetes mellitus | Regend Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGEND003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07275788 ↗ |
| Modality | Cell therapy | “REGEND003, which consists of human kidney progenitor cells” NCT07275788 ↗ |